Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2020  |  Volume : 33  |  Issue : 2  |  Page : 492-496

Effects of cabergoline administration on uterine perfusion in women with polycystic ovarian syndrome


1 Department of Obstetrics and Gynecology, Faculty of Medicine, Menoufia University, Menoufia, Egypt
2 Department of Obstetrics and Gynecology, El Tahrir General Hospital, El Tahrir, Al Behera, Egypt

Correspondence Address:
Hanaa H. AbdelMagied Gafar
El Tahrir General Hospital, Al Behera Governorate
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/mmj.mmj_299_19

Rights and Permissions

Objective The objective of this study was to assess the effects of cabergoline administration on uterine blood flow in women suffering from polycystic ovarian syndrome (PCOS). Background Many women with PCOs experience infrequent ovulation or lack of ovulation altogether and may face many challenges in becoming pregnant. Patients and methods A randomized controlled study was conducted on 108 patients with PCOS who attended the Shebin El-Kom Teaching Hospital outpatient clinic during the period spanning from May 2016 to March 2018. Doppler ultrasound was performed for both groups. Then weekly dose of cabergoline 0.5 mg was administrated for the case group for 12 weeks, while the control group did not receive any treatment. At the end of 12th week, another Doppler ultrasound was performed for all participants, and the results were recorded. Results There was no significant difference between the two groups with regard to age, BMI, luteinizing hormone and follicle-stimulating hormone levels. Before the intervention, the uterine pulsatility index and resistance index, and the ovarian stromal pulsatility index and resistance index, showed no significant difference between the case and control groups. Before treatment, 45 patients from the case group had oligomenorrhea, and, after treatment with cabergoline, 40 patients showed regular menstrual cycle. Side effects (vomiting and blurred vision) occurred in four patients from the case group; hence, they were excluded, and four patients (two got pregnant and two were on treatment) were also excluded during booking of the patients. Conclusion PCOS patients were shown to have more resistance in uterine blood flow and lower ovarian resistance than healthy people. Cabergoline administration proved to increase uterine blood perfusion, increase ovarian stromal resistance, and regulate the menstruation cycle.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed261    
    Printed13    
    Emailed0    
    PDF Downloaded27    
    Comments [Add]    

Recommend this journal